Latest Intelligence in Switzerland

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Roche: buying up for biotech boost

Roche has announced that it will acquire GlycArt for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology, markets. The deal promises to strengthen Roche's drug development capabilities and help maintain the large increases in sales drawn from its therapeutic anti-cancer antibodies.

Published By Datamonitor
20 Jul 2005
CommentWire
CommentWire

Roche: building a strong hepatitis C portfolio

Published By Datamonitor
03 Jul 2001
CommentWire
CommentWire

Roche/Schering-Plough: competing in drug markets, not courts

Published By Datamonitor
14 Aug 2001
CommentWire
CommentWire

Roche/GSK: monthly formulation puts Boniva in pole position

The green light for Boniva sees it join Merck & Co's [MRK] Fosamax and Aventis's [SNY] Actonel as the newest member of the bisphosphonate family - a class of drugs that treat osteoporosis by increasing bone mineral density. Adherence to bisphosphonate regimens can be difficult for many patients, but Boniva's monthly formulation offers a major advance in overcoming this issue.

Published By Datamonitor
30 Mar 2005
CommentWire
CommentWire

Roche/Genentech: Herceptin poised for an expanded role

Scientists have found that HER-2 is a key contributor to the development of pre-invasive breast cancer. Roche/Genentech's Herceptin, currently used to treat advanced breast cancer, can target HER-2. However, the detection of elevated HER-2 is not routine among most physicians. Despite this, Herceptin is well positioned to build its usage in early-stage and pre-cancerous populations.

Published By Datamonitor
14 Apr 2003
CommentWire
CommentWire

Roche/deCODE: a renewed partnership

Published By Datamonitor
07 Mar 2001
CommentWire
CommentWire

Roche/Chugai: pharmaceuticals consolidation reaches Japan

The Swiss pharmaceutical giant Roche arose from slumber earlier this week, announcing its merger with Chugai. Although the move will benefit both Roche and Chugai, and marks an important milestone in the globalization of the industry in Japan, Roche still needs to do more to accelerate its growth and catch up with its peers.

Published By Datamonitor
12 Dec 2001
CommentWire
CommentWire

Roche/Chugai: gather more positive data for Actemra

The latest Phase III study results for Actemra confirm previous findings that the drug is a safe and effective biologic therapy for rheumatoid arthritis sufferers. In particular, Actemra will be a therapy for niche rheumatoid arthritis patients who do not adequately respond to anti-TNF or traditional disease-modifying drugs, further strengthening the immunology franchise of Roche and Chugai.

Published By Datamonitor
12 Jul 2007
Expert View
Expert View

Roche reinforces its HIV portfolio

Recently presented data has highlighted the efficacy of Roche and Trimeris' Fuzeon plus new antiretrovirals in treatment-experienced HIV patients. The data forms part of an ongoing program of studies into the use of Fuzeon with several pipeline drugs, including the novel CCR5 inhibitors, and underlines Roche's continued commitment to the HIV market. Datamonitor's Laura Harris reports...

Published By Datamonitor
02 Aug 2005
CommentWire
CommentWire

Richemont: well placed for luxury goods growth

Richemont is benefiting from strong demand in the luxury goods sector as consumers embrace top-end products from big name design houses, particularly for accessories. Richemont, with interests in luxury jewelry, watches, leather goods and writing instruments, is well positioned for growth.

Published By Datamonitor
20 Nov 2006

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.